Alzheimer's Disease (Central Nervous System) Drugs In Development, 2021 Market Research Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 23, 62, 86, 1, 4, 358, 178 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 3, 107 and 52 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Key Topics Covered:

• Introduction
• Alzheimer's Disease - Overview
• Alzheimer's Disease - Therapeutics Development
• Alzheimer's Disease - Therapeutics Assessment
• Alzheimer's Disease - Companies Involved in Therapeutics Development
• Alzheimer's Disease - Drug Profiles
• Alzheimer's Disease - Dormant Projects
• Alzheimer's Disease - Discontinued Products
• Alzheimer's Disease - Product Development Milestones
• Appendix

Companies Mentioned

• 1st Bio Therapeutics Inc
• 2A Pharma AB
• 4B Technologies (Suzhou) Co Ltd
• 4P-Pharma SAS
• AB Science SA
• Abaxy Sprl
• AbbVie Inc
• Abrexa Pharmaceuticals Inc
• AC Immune SA
• Acadia Pharmaceuticals Inc
• Accuitis Pharmaceuticals Inc
• Acelot Inc
• Actinogen Medical Ltd
• Acumen Pharmaceuticals Inc
• Addex Therapeutics Ltd
• ADEL Inc
• Adocia SAS
• ADRx Inc
• Aerobyx LLC
• Avidin Biotechnology Ltd
• Avineuro Pharmaceuticals Inc
• Axon Neuroscience SE
• Axxam SpA
• AZTherapies Inc
• Berg LLC
• BeyondBio Inc
• Bio-Pharm Solutions Co Ltd
• BioArctic AB
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Biom Therapeutics LLC
• Biorchestra Ltd
• BioSplice Therapeutics Inc
• BioVie Inc
• BioXcel Therapeutics Inc
• Bisichem Co Ltd
• Boehringer Ingelheim International GmbH
• Bolden Therapeutics Inc
• Bolder Biotechnology Inc
• Boryung Pharmaceutical Co Ltd
• Brain Innovation Co Ltd
• BrainStorm Cell Therapeutics Inc
• Brainvectis SAS
• Corium Inc
• Cortexyme Inc
• Cortice Biosciences Inc
• Covalent Bioscience Inc
• Coya Therapeutics Inc
• Creative Bio-Peptides Inc
• Crossbeta Biosciences BV
• CuroNZ Ltd
• Cyclerion Therapeutics Inc
• Cyclo Therapeutics Inc
• CycloLab Cyclodextrin Research and Development Laboratory Ltd
• Dadang & BIO Co Ltd
• Daewoong Pharmaceutical Co Ltd
• Immunwork Inc
• Inmune Bio Inc
• InnoBioscience LLC
• InnoPharmaScreen Inc
• Kwang Dong Pharmaceutical Co Ltd
• Kyowa Kirin Co Ltd
• Lacerta Therapeutics Inc
• Landos Biopharma Inc
• Lauren Sciences LLC
• Lead Discovery Center GmbH
• LEXEO Therapeutics LLC
• Libella Gene Therapeutics
• Light Chain Bioscience
• Longeveron Inc
• LSL Neurosciences LLC
• Lyndra Therapeutics Inc.
• MetrioPharm AG
• MetVital Inc
• MGC Pharmaceuticals Ltd
• Mindset Pharma Inc
• Mission Therapeutics Ltd
• Mitoconix Bio Ltd
• Modag GmbH
• Montisera Ltd
• NAL Pharmaceuticals Ltd
• Nanomerics Ltd
• NatureWise Biotech & Medicals Corp
• Neonc Technologies Inc
• NeoNeuro SAS
• NeoProgen Inc
• NervGen Pharma Corp
• NeuExcell Therapeutics Inc
• Neuracle Science Co Ltd
• Oleolive LLC
• Oligomerix inc
• OncoSynergy Inc
• Ono Pharmaceutical Co Ltd
• Opsona Therapeutics Ltd
• Orpheris Inc
• Orphi Therapeutics Inc
• Oryzon Genomics SA
• OTR3 SAS
• Overseas Pharmaceuticals Ltd
• Oxstem Ltd
• P2D Inc
• Palisade Bio, Inc
• Panorama Researchama Research
• Paramag Biosciences
• Transposon Therapeutics Inc
• Treeway BV
• Treventis Corp
• Tria Bioscience Corp
• Triplet Therapeutics Inc
• TrueBinding Inc
• UCB SA
• Uni-Bio Science Group Ltd
• Unity Biotechnology Inc
• USA Elixiria Biotech Inc
• Vaccinex Inc
• Vanworld Pharmaceutical (Rugao) Company Ltd
• Varinel Inc
• Vaxxinity Inc
• VectorY Therapeutics Inc
• VFP Therapies
• Videns Incorp Ltd
• Virogenics Inc
• Vitruvian Biomedical Inc
• Vivoryon Therapeutics NV
• Vivreon Biosciences LLC
• Voronoi Group
• Voyager Therapeutics Inc
• Vybion Inc
• Whan In Pharm Co Ltd
• Wren Therapeutics Ltd
• Xcelthera INC
• Xenexus Pharmaceuticals Pty Ltd
• Xigen SA
• Xonovo Inc
• Yasham P2D Lifesciences Pvt Ltd
• Yuhan Corp
• Yuma Therapeutics Corp
• Yumanity Therapeutics Inc
• Zensun (Shanghai) Sci & Tech Co Ltd
• Zhejiang Hisun Pharmaceutical Co Ltd
• Zhejiang Huahai Pharmaceutical Co Ltd
• Zhittya Genesis Medicine Inc
• ZZ Biotech LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u1tbn1

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900